PHAT

11.33

2.24% -0.26

Handel nachbörslich: 11.46 0.13 +1.15%

Phathom Pharmaceuticals Inc (PHAT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$11.59

Offen:

$11.7

24-Stunden-Volumen:

1.44M

Relative Volume:

1.35

Marktkapitalisierung:

$899.94M

Einnahmen:

$175.11M

Nettoeinkommen (Verlust:

$-221.25M

KGV:

-3.7129

EPS:

-3.0515

Netto-Cashflow:

$-167.00M

1W Leistung:

-12.03%

1M Leistung:

+7.09%

6M Leistung:

-16.32%

1J Leistung:

+173.01%

1-Tages-Spanne:

$11.08

$11.81

1-Wochen-Bereich:

$11.08

$13.18

52-Wochen-Spanne:

$2.21

$18.31

Phathom Pharmaceuticals Inc Stock (PHAT) Company Profile

Firmenname

Phathom Pharmaceuticals Inc

Sektor

Healthcare (1107)

Branche

Biotechnology (620)

Telefon

(877) 742-8466

Adresse

100 CAMPUS DRIVE,, FLORHAM PARK, NJ

Mitarbeiter

371

Twitter

Nächster Verdiensttermin

2026-04-30

Neueste SEC-Einreichungen

PHAT's Discussions on Twitter

Compare PHAT vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PHAT Phathom Pharmaceuticals Inc	11.33	920.60M	175.11M	-221.25M	-167.00M	-3.0515
VRTX Vertex Pharmaceuticals Inc	430.14	108.36B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	731.77	78.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	775.03	48.74B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	302.11	41.16B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	298.16	33.17B	5.36B	287.73M	924.18M	2.5229

Phathom Pharmaceuticals Inc Stock (PHAT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-27	Hochstufung	Barclays	Equal Weight → Overweight
2025-12-12	Eingeleitet	Raymond James	Strong Buy
2025-12-09	Eingeleitet	Barclays	Equal Weight
2025-02-14	Eingeleitet	Cantor Fitzgerald	Overweight
2024-05-03	Eingeleitet	Stifel	Buy
2024-01-05	Bestätigt	Needham	Buy
2023-08-09	Eingeleitet	H.C. Wainwright	Buy
2023-05-11	Hochstufung	Evercore ISI	In-line → Outperform
2023-03-13	Eingeleitet	Craig Hallum	Buy
2022-10-21	Eingeleitet	Jefferies	Buy
2022-05-06	Herabstufung	Evercore ISI	Outperform → In-line
2021-05-12	Hochstufung	Goldman	Sell → Neutral
2021-02-17	Eingeleitet	BMO Capital Markets	Outperform
2021-02-02	Eingeleitet	Guggenheim	Buy
2020-06-26	Herabstufung	Goldman	Neutral → Sell
2019-11-20	Eingeleitet	Evercore ISI	Outperform
2019-11-19	Eingeleitet	Goldman	Neutral
2019-11-19	Eingeleitet	Jefferies	Buy
2019-11-19	Eingeleitet	Needham	Buy

Alle ansehen

Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten

05:50 AM

Phathom upgraded at Barclays following pullback, Voquezna optimism - MSN

05:50 AM

02:44 AM

Phathom says FDA confirmed Voqueza exclusivity through May 2032 - MSN

02:44 AM

Apr 27, 2026

Wall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a Bet - MSN

Apr 27, 2026

Apr 26, 2026

Phantom slumps 12%; prices $130M stock at $16 per share - MSN

Apr 26, 2026

Barclays upgrades Phathom Pharmaceuticals (PHAT) - MSN

Apr 26, 2026

HC Wainwright & Co. Maintains Phathom Pharmaceuticals (PHAT) Buy Recommendation - MSN

Apr 26, 2026

Apr 25, 2026

Phathom Pharmaceuticals brings senior marketing leader to ThinkDHC patient engagement event - Traders Union

Apr 25, 2026

Apr 24, 2026

Phathom Pharmaceuticals (PHAT) Projected to Post Earnings on Thursday - MarketBeat

Apr 24, 2026

Apr 23, 2026

PHAT (Phathom Pharmaceuticals Inc.) reports narrower than expected Q4 2025 loss, pushing shares up 4.6 percent in today’s trading.Market Buzz Alerts - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Apr 22, 2026

(PHAT) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 22, 2026

PHAT (Phathom Pharmaceuticals Inc.) posts narrower than expected Q4 2025 loss, shares rise modestly in today’s regular trading.Earnings Quality - Cổng thông tin điện tử Tỉnh Sơn La

Apr 22, 2026

Apr 21, 2026

Phathom Pharmaceuticals (NASDAQ:PHAT) Shares Down 6.8%Time to Sell? - MarketBeat

Apr 21, 2026

Apr 20, 2026

Phathom Pharmaceuticals (PHAT) Stock: Suitable for Investors? (+1.97%) 2026-04-20Trend Following - Cổng thông tin điện tử tỉnh Lào Cai

Apr 20, 2026

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, April 30, 2026 - The Manila Times

Apr 20, 2026

Phathom to pair Q1 results with a business update in April 30 webcast - Stock Titan

Apr 20, 2026

Phathom Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide Business ... - Caledonian Record

Apr 20, 2026

Apr 17, 2026

Assessing Phathom Pharmaceuticals (PHAT) Valuation After Strong One Year Shareholder Return - Yahoo Finance

Apr 17, 2026

Apr 16, 2026

Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28 - 富途牛牛

Apr 16, 2026

Phathom Pharmaceuticals (PHAT) Stock Analysis: A Potential 85% Upside Awaits Investors - DirectorsTalk Interviews

Apr 16, 2026

Phathom surges 125% after FDA grants petition on Voquezna exclusivity - MSN

Apr 16, 2026

Apr 14, 2026

Phathom Pharmaceuticals surges 50% following large insider purchase - MSN

Apr 14, 2026

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Apr 14, 2026

Apr 13, 2026

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.

Apr 13, 2026

Apr 12, 2026

Responsive Playbooks and the PHAT Inflection - Stock Traders Daily

Apr 12, 2026

Apr 09, 2026

PHAT Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Apr 09, 2026

Apr 08, 2026

Aug Highlights: Is Phathom Pharmaceuticals Inc a cyclical or defensive stock2026 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn

Apr 08, 2026

Apr 07, 2026

[ARS] Phathom Pharmaceuticals, Inc. SEC Filing - Stock Titan

Apr 07, 2026

Phathom Pharmaceuticals (NASDAQ: PHAT) sets 2026 virtual meeting, director elections and say-on-pay vote - Stock Titan

Apr 07, 2026

Apr 06, 2026

Quarterly Recap: How correlated is Phathom Pharmaceuticals Inc to the S P5002026 Sector Moves & Fast Gaining Stock Reports - baoquankhu1.vn

Apr 06, 2026

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewswire

Apr 06, 2026

Apr 05, 2026

Portfolio Recap: Is Phathom Pharmaceuticals Inc a cyclical or defensive stockQuarterly Profit Report & Weekly Stock Breakout Alerts - baoquankhu1.vn

Apr 05, 2026

Apr 04, 2026

PHAT Technical Analysis & Stock Price Forecast - Intellectia AI

Apr 04, 2026

Apr 02, 2026

Hennion & Walsh Asset Management Inc. Buys New Shares in Phathom Pharmaceuticals, Inc. $PHAT - MarketBeat

Apr 02, 2026

Apr 01, 2026

PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 01, 2026

Mar 31, 2026

Understanding the Setup: (PHAT) and Scalable Risk - Stock Traders Daily

Mar 31, 2026

Mar 30, 2026

Portfolio Recap: What are the risks of holding Phathom Pharmaceuticals IncWeekly Trend Report & Weekly High Return Forecasts - baoquankhu1.vn

Mar 30, 2026

Mar 28, 2026